FDA approves breakthrough pancreatic cancer treatment

FDA approves new pancreatic cancer drug that could extend patients' lives

Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.

Doctor explains what FDA'a approval of pancreatic cancer drug could mean for patients

The FDA has approved a drug that could extend the life of patients with late-stage pancreatic cancer. CBS News' medical correspondent Dr. Céline Gounder has more.

FDA approves pancreatic cancer drug that extends patients’ lives

FDA approves breakthrough pancreatic cancer treatment

FDA approves new drug Rasonque to treat advanced pancreatic cancer

The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease. A large trial found the once-daily pill doubled survival rates, offering fresh hope for people who have exhausted other treatments.

FDA approves first-of-a-kind pancreatic cancer drug trialed in Boston

US drug agency approves breakthrough treatment for pancreatic cancer

Experts have hailed the drug, daraxonrasib, as a game changer for one of the world's deadliest cancers.

FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double

Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.

A Game-Changing Drug for Pancreatic Cancer Just Got FDA Approval

In a large-scale clinical trial, people taking daraxonrasib lived twice as long as those given standard chemotherapy.

FDA approves pancreatic cancer drug taken by Ben Sasse in clinical trials, made available in Omaha

F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

FDA approves landmark pancreatic cancer drug that's shown to improve survival

WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer. FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases. It's an approach that previously eluded drugmakers for decades. The daily pills will be sold by Revolution Medicines under the brand name Rasonque. Patients taking the ...